Q-omics provides the consensus-scored ADAM20 profile across patient tissues and cancer cell-line models. ADAM20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ADAM20 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, ADAM20 RNA expression shows 17,899 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUSC, and THYM as cancer lineages where ADAM20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM20 survival associations across molecular data types. ADAM20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM20 RNA expression–survival associations across cancer types. High ADAM20 expression shows unfavorable associations in ACC, KIRC, CESC and OV, but favorable associations in LUSC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for ADAM20 RNA expression.
This table summarizes ADAM20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAM20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM20 shows lower tumor expression in THCA, KICH, UCEC and BRCA and higher tumor expression in LUSC and COAD. The LUSC box plot shows higher ADAM20 RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p < 0.001).
This table shows molecular features associated with ADAM20 in patient tissues and cancer cell lines. In patient samples, ADAM20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
